English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduBACKGROUNDRecent advancements in nanomedicine have highlighted the potential of exosome (Ex)-based therapies, utilizing naturally derived nanoparticles, as a novel approach to targeted cancer treatment. AIMTo explore the targetability and
Tag: Targeted Therapy
How New Therapies Are Revolutionizing the Treatment of Juvenile Idiopathic Arthritis
The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to Rutgers Health researchers.
Trastuzumab deruxtecan significantly outperforms chemotherapy for the treatment of advanced breast cancer
A new study published in NEJM and led by global principal investigator Aditya Bardia, MD, director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, found trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, significantly improves progression-free survival compared to…
MD Anderson Research Highlights for August 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights: EHA 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights for June 5, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
New Frontiers in Treating GI Cancers
Gastrointestinal cancers were once diagnosed primarily by location. A tumor in the liver was liver cancer, while one in the pancreas was pancreatic. The few chemotherapy treatments available affected the entire patient—sometimes causing difficult side effects.
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.
New drug delays progression of glioma, a deadly brain cancer
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.
MD Anderson Research Highlights: AACR 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the American Association for Cancer Research (AACR) Annual Meeting 2023.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
MD Anderson Research Highlights for February 1, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies.
MD Anderson Research Highlights for October 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a combination approach to overcome PARP inhibitor resistance in breast and ovarian cancers, a deeper understanding of STAT3 mutations as drivers of disease progression, insights into the “obesity paradox” in men with advanced melanoma, a prognostic model for rapidly progressing vestibular schwannoma, and a role for cellular trafficking proteins in creating a metastasis-promoting lung cancer microenvironment.
MD Anderson Research Highlights for August 24, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include confirmation of improving response rates in Phase I trials over the last 20 years, a novel targeted therapy combination and biomarkers of response for chimeric antigen receptor (CAR) T cell therapy in B-cell lymphomas, a combination therapy for patients with melanoma brain metastases, and new treatment options for metastatic sarcomas, HPV-driven cancers and uterine cancer.
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.
MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
Chula Excellence Cancer Center collabs with medical specialists from various fields to enhance treatment capabilities.
Chula now has an Excellence Chulalongkorn Comprehensive Cancer Center bringing together medical specialists from various areas of expertise to attend to cancer patients using the latest academic and technological know-how to enhance the quality of life and the possibilities of being cured for patients of all types of cancer.
‘Research autopsy’ helps scientists study why certain cancer therapies stop working
A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.
MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development
MD Anderson and Blueprint Medicines announced a three-year strategic collaboration to accelerate the development of BLU-222, an investigational targeted therapy against CDK2.
Combination targeted therapy provides durable remission for patients with chronic lymphocytic leukemia
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
New combination therapy could help fight difficult-to-treat cancers with common mutations
UCLA scientists describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. This combination of two small molecules has the potential to treat not only BRAF mutated melanoma but also additional aggressive subtypes of cancers, including melanoma, lung, pancreatic and colon cancers that harbor common mutations in cancer genes called RAS or NF1.
Roswell Park Leukemia Chief Shares Promising Findings on New Treatment Options at ASH 2020
Today, during the ASH Annual Meeting and Exposition, Eunice Wang, MD, Chief of Leukemia and Director of Infusion Services at Roswell Park Comprehensive Cancer Center, is presenting data on two ongoing studies incorporating new treatment options for AML.
New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the enolase enzyme.
ORNL researcher studies individualized isotopes’ impact by targeting cancer
A radioisotope researcher in the Radioisotope Science and Technology Division at the Department of Energy’s Oak Ridge National Laboratory, Davern is focusing on ways to use nanoparticles — particles 100 nanometers or smaller that can have special properties — to contain those radioisotopes and deliver them directly to cancer cells, where they can decay into different isotopes that irradiate those cells.
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study
Brain’s Immune Cells Promising Cellular Target for Therapeutics
Inspired by the need for new and better therapies for neurodegenerative diseases, Rutgers University researchers are exploring the link between uncontrolled inflammation within the brain and the brain’s immune cells, known as microglia, which are emerging as a promising cellular target because of the prominent role they play in brain inflammation. In APL Bioengineering, the group highlights the design considerations and benefits of creating therapeutic nanoparticles for carrying pharmacological factors directly to the sites of the microglia.
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Superior Progression-Free Survival Associated with Continuous Targeted Therapy Combination for BRAF-mutated Melanoma
Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.
Drug used for breast, kidney cancers may also extend survival for patients with advanced head and neck cancer
A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the mTOR inhibitor everolimus were more likely to be cancer-free a year after therapy than those who took a placebo drug, and the benefit persisted for those with mutations in their TP53 gene.
Science Snapshot From Berkeley Lab – a biocompatible material that turns up the heat on antibacterial-resistant diseases
Scientists at Berkeley Lab’s Molecular Foundry have designed a biocompatible polymer that has the potential to advance photothermal therapy, a technique that deploys near-infrared light to combat antibacterial-resistant infections and cancer.
MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.